|
|
Article: FDA Approves Cubicin, Previously Cidecin, an Antibiotic Developed by Cubist Pharmaceuticals.
- Article from:
- Business Wire
- Article date:
- September 12, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
BIOWIRE2K
LEXINGTON, Mass.--(BUSINESS WIRE)--Sept. 12, 2003
The Only Once-Daily, Rapidly Bactericidal Antibiotic Proven
Effective Against Both MRSA and MSSA
Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that the U.S. Food & Drug Administration (FDA) has approved Cubicin(TM) (daptomycin for injection; previously known as Cidecin(R)) for the treatment of complicated skin and skin structure (cSSS) infections caused by Gram-positive bacteria, including those caused by MRSA (methicillin-resistant Staphylococcus aureus) and MSSA (methicillin-susceptible S. aureus). Cubist ...